Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mar

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advanced RCC After Immunotherapy Belzutifan Plus Lenvatinib or Cabozantinib

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Stereotactic vs Whole-Brain Radiation for Patients With Brain Metastases

Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions